GALDERMA GRP AG
204,70€
+4,90 (+2,45%)
29.10.2026, 12:16:38 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Zuletzt angesehen
- KAROON ENERGY LTD. +0,08 +7,45% 1,06€
- Arete PRIME VALUES... +1,47 +1,02% 145,43€
- INTERPUMP GRP EO... +0,78 +2,13% 37,74€
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 199,80€ | +2,45% |
| 1 Woche | 188,26€ | +6,50% |
| 1 Monat | 172,60€ | +16,16% |
| 6 Monate | 170,60€ | +17,53% |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 204,70€ |
| Schluss Vortag | 199,80€ |
| Eröffnung | 199,95€ |
| Geld | 205,20€ |
| Brief | 205,30€ |
| Tages-Hoch | 204,70€ |
| Tages-Tief | 199,35€ |
| 52 Wochen-Hoch | 209,80€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 209,80€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines - 23.10.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance - 22.10.2026, 07:00:07 Uhr
- BUSINESS WIRE: AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership - 21.10.2026, 07:00:04 Uhr
- BUSINESS WIRE: PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis - 15.10.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering - 14.10.2026, 07:00:05 Uhr
- BUSINESS WIRE: New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing - 13.10.2026, 07:00:06 Uhr
- BUSINESS WIRE: Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older - 08.10.2026, 07:00:07 Uhr
- BUSINESS WIRE: 30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation - 06.10.2026, 07:00:03 Uhr
- BUSINESS WIRE: EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - 30.09.2026, 07:00:02 Uhr
- BUSINESS WIRE: EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences - 23.09.2026, 07:00:06 Uhr
